{
    "id": 26632,
    "fullName": "IL3RA positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "IL3RA positive indicates the presence of the IL3RA gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3563,
        "geneSymbol": "IL3RA",
        "terms": [
            "IL3RA",
            "CD123",
            "hIL-3Ra",
            "IL3R",
            "IL3RAY",
            "IL3RX",
            "IL3RY"
        ]
    },
    "variant": "positive",
    "createDate": "05/30/2017",
    "updateDate": "05/30/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11024,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talacotuzumab (JNJ-56022473) increased antibody-dependent cell-mediated cytotoxicity (ADCC) in acute myeloid leukemia (AML) cell lines expressing IL3RA (CD123) in culture, with cell lines expressing higher levels of IL3RA (CD123) demonstrating increased ADCC activity (Blood Dec 2015, 126 (23) 4946).",
            "molecularProfile": {
                "id": 27892,
                "profileName": "IL3RA positive"
            },
            "therapy": {
                "id": 5809,
                "therapyName": "Talacotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9014,
                    "pubMedId": null,
                    "title": "Preclinical Evaluation of CSL362/JNJ-56022473 Single Agent in in Vitro Assays",
                    "url": "http://www.bloodjournal.org/content/126/23/4946?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12813,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGN-CD123A induced death of acute myeloid leukemia cells expressing IL3RA in culture, and reduced tumor growth, improved survival, and led to durable remissions in cell-line xenograft models (PMID: 29142066).",
            "molecularProfile": {
                "id": 27892,
                "profileName": "IL3RA positive"
            },
            "therapy": {
                "id": 6677,
                "therapyName": "SGN-CD123A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10746,
                    "pubMedId": 29142066,
                    "title": "Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29142066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12814,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGN-CD123A resulted in delayed tumor growth and induced remission in acute myeloid cell line xenograft models expressing IL3RA and harboring a FLT3 ITD mutation (PMID: 29142066).",
            "molecularProfile": {
                "id": 28930,
                "profileName": "FLT3 exon 14 ins IL3RA pos"
            },
            "therapy": {
                "id": 6677,
                "therapyName": "SGN-CD123A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10746,
                    "pubMedId": 29142066,
                    "title": "Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29142066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12815,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Quizartinib (AC220) and SGN-CD123A resulted in greater antitumor activity and more durable remissions than when treated with SGN-CD123A alone in acute myeloid leukemia cell line xenograft models expressing IL3RA and harboring a FLT3 ITD mutation (PMID: 29142066).",
            "molecularProfile": {
                "id": 28930,
                "profileName": "FLT3 exon 14 ins IL3RA pos"
            },
            "therapy": {
                "id": 6678,
                "therapyName": "Quizartinib + SGN-CD123A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10746,
                    "pubMedId": 29142066,
                    "title": "Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29142066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27892,
            "profileName": "IL3RA positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28930,
            "profileName": "FLT3 exon 14 ins IL3RA pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}